RSS

CHMP

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

A positive opinion has been adopted by the CHMP of the European Medicines Agency, recommending a change to the terms of the marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) to include first-line treatment. more

News

Amgen and Allergan have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorisation of ABP 980, a biosimilar to Herceptin (trastuzumab). more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Juluca treatment for HIV-1. more

News

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the marketing authorisation of Lynparza (olaparib) tablets for patients with platinum-sensitive relapsed ovarian, fallopian tube, or primary perito more

News

The EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra (emicizumab) — Roche’s prophylactic treatment for people with haemophilia A with inhibitors. more

News

With festivities and holidays galore during the latter part of December we thought it would be a good idea to briefly run through some of the pharma news that came out in the run up to Christmas. more

News

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing authorisation in the EU for Janssen-Cilag International’s guselkumab — a treatment for moderate to severe plaque psoriasis. more

News

Swiss specialty pharmaceutical company, Santhera Pharmaceuticals, has received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its revised marketing authorisation application for Raxone in DMD more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for a once-daily darunavir-based single tablet regimen (STR) for the treatment of HIV. more

News

Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for marketing authorization of Dupixent (dupilumab). more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion, recommending that biosimilar Imraldi be granted marketing authorisation. more

News

Merck has announced that the CHMP of the EMA has issued a positive opinion for approval of Cladribine tablets for the treatment of relapsing forms of multiple sclerosis (RMS) in patients with high disease activity. more

News

Veltassa (patiromer), developed by Relypsa, has received a recommendation for marketing approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of hyperkalaemia. more

News

Sanofi and Regeneron have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the marketing authorisation of Kevzara (sarilumab). more

News

The CHMP has given a positive opinion recommending that Biogen’s treatment for patients with spinal muscular atrophy (SMA), SPINRAZA (nusinersen), be granted marketing authorisation. more

News

During its March 2017 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended six medicines for approval, including three orphans. more

News

Novo Nordisk has announced that CHMP has adopted a positive opinion for Xultophy, the first ever once-daily basal insulin and GLP-1 analogue in one pen. more